This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Low-Grade Serous Ovarian Carcinoma (LGSOC) with a specific focus on VS-6766 and trametinib
Ticker(s): VSTM, NVSWho's the expert?
Institution: MD Anderson
- Professor of Gynecologic Oncology at MD Anderson & Co-Principal Investigator of M.D. Anderson’s NCI-funded SPORE in Ovarian Cancer.
- Research is focused on ovarian cancer, particularly translational studies of rare ovarian tumors: low-grade serous tumors (serous tumors of low malignant potential and low-grade serous carcinomas), clear cell carcinomas, mucinous carcinomas, malignant ovarian germ cell tumors, and sex cord-stromal ovarian tumors.
- Principal investigator or co-principal investigator of clinical trials focused on novel therapeutics for patients with low-grade serous carcinoma of the ovary and has served as a member of the NCI’s Gynecologic Cancer Steering Committee, which approves all new phase III and randomized phase II clinical trials for gynecologic cancers in North America.
Interview GoalThis conversation will focus on the patient population for Low-Grade Serous Ovarian Carcinoma (LGSOC) and the potential of Verastem's VS-6766
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
